• Je něco špatně v tomto záznamu ?

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

M. Jaruskova, N. Curik, R. Hercog, V. Polivkova, E. Motlova, V. Benes, H. Klamova, P. Pecherkova, P. Belohlavkova, F. Vrbacky, K. Machova Polakova,

. 2017 ; 36 (1) : 55. [pub] 20170418

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016656

BACKGROUND: Through high-throughput next-generation sequencing of promoters of solute carrier and ATP-binding cassette genes, which encode drug transporters, we aimed to identify SNPs associated with the response to imatinib administered for first-line treatment of patients with chronic myeloid leukemia. METHODS: In silico analysis using publicly available databases was done to select the SLC and ABC genes and their promoters for the next-generation sequencing. SNPs associated with the imatinib response were identified using Fisher's exact probability tests and subjected to the linkage disequilibrium analyses with regulatory loci of concerned genes. We analyzed cumulative achievement of major molecular response and probability of event free survival in relation to identified SNP genotypes in 129 CML patients and performed multivariate analysis for determination of genotypes as independent predictors of outcome. Gene expression analysis of eight cell lines naturally carrying different genotypes was performed to outline an impact of genotypes on the gene expression. RESULTS: We observed significant differences in the frequencies of the rs460089-GC and rs460089-GG (SLC22A4) genotypes among rs2631365-TC (SLC22A5) genotype carriers that were associated with optimal and non-optimal responses, respectively. Loci rs460089 and rs2631365 were in highly significant linkage disequilibrium with 12 regulatory loci in introns of SLC22A4 and SLC22A5 encoding imatinib transporters. Genotype association analysis with the response to imatinib indicated that rs460089-GC carriers had a significantly higher probability of achieving a stable major molecular response (BCR-ABL1 transcript level below or equal to 0.1% in the international scale). In contrast, the rs460089-GG represented a risk factor for imatinib failure, which was significantly higher in rs460089-GG_rs2631365-TC carriers. CONCLUSIONS: This exploratory study depicted potentially important genetic markers predicting outcome of imatinib treatment, which may be helpful for tailoring therapy in clinical practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016656
003      
CZ-PrNML
005      
20180521101130.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13046-017-0523-3 $2 doi
035    __
$a (PubMed)28420426
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Jaruskova, Monika $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic. Institute of Clinical and Experimental Hematology, 1st Medicine Faculty, Charles University, Prague, Czech Republic.
245    10
$a Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment / $c M. Jaruskova, N. Curik, R. Hercog, V. Polivkova, E. Motlova, V. Benes, H. Klamova, P. Pecherkova, P. Belohlavkova, F. Vrbacky, K. Machova Polakova,
520    9_
$a BACKGROUND: Through high-throughput next-generation sequencing of promoters of solute carrier and ATP-binding cassette genes, which encode drug transporters, we aimed to identify SNPs associated with the response to imatinib administered for first-line treatment of patients with chronic myeloid leukemia. METHODS: In silico analysis using publicly available databases was done to select the SLC and ABC genes and their promoters for the next-generation sequencing. SNPs associated with the imatinib response were identified using Fisher's exact probability tests and subjected to the linkage disequilibrium analyses with regulatory loci of concerned genes. We analyzed cumulative achievement of major molecular response and probability of event free survival in relation to identified SNP genotypes in 129 CML patients and performed multivariate analysis for determination of genotypes as independent predictors of outcome. Gene expression analysis of eight cell lines naturally carrying different genotypes was performed to outline an impact of genotypes on the gene expression. RESULTS: We observed significant differences in the frequencies of the rs460089-GC and rs460089-GG (SLC22A4) genotypes among rs2631365-TC (SLC22A5) genotype carriers that were associated with optimal and non-optimal responses, respectively. Loci rs460089 and rs2631365 were in highly significant linkage disequilibrium with 12 regulatory loci in introns of SLC22A4 and SLC22A5 encoding imatinib transporters. Genotype association analysis with the response to imatinib indicated that rs460089-GC carriers had a significantly higher probability of achieving a stable major molecular response (BCR-ABL1 transcript level below or equal to 0.1% in the international scale). In contrast, the rs460089-GG represented a risk factor for imatinib failure, which was significantly higher in rs460089-GG_rs2631365-TC carriers. CONCLUSIONS: This exploratory study depicted potentially important genetic markers predicting outcome of imatinib treatment, which may be helpful for tailoring therapy in clinical practice.
650    _2
$a antitumorózní látky $x aplikace a dávkování $x terapeutické užití $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genotyp $7 D005838
650    _2
$a vysoce účinné nukleotidové sekvenování $x metody $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a imatinib mesylát $x aplikace a dávkování $x terapeutické užití $7 D000068877
650    _2
$a buňky K562 $7 D020014
650    _2
$a chronická myeloidní leukemie $x farmakoterapie $x genetika $7 D015464
650    _2
$a vazebná nerovnováha $7 D015810
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutační rychlost $7 D059645
650    _2
$a proteiny přenášející organické kationty $x genetika $7 D027701
650    12
$a jednonukleotidový polymorfismus $7 D020641
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a sekvenční analýza DNA $x metody $7 D017422
650    _2
$a rodina nosičů rozpuštěných látek 22, člen 5 $x genetika $7 D000074058
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Curik, Nikola $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic. Institute of Pathophysiology, 1st Medicine Faculty, Charles University, Prague, Czech Republic.
700    1_
$a Hercog, Rajna $u European Molecular Biology Laboratory, Genomics Core Facility, Heidelberg, Germany.
700    1_
$a Polivkova, Vaclava $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic. Faculty of Science, Charles University, Prague, Czech Republic.
700    1_
$a Motlova, Eliska $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic.
700    1_
$a Benes, Vladimir $u European Molecular Biology Laboratory, Genomics Core Facility, Heidelberg, Germany.
700    1_
$a Klamova, Hana $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic. Institute of Clinical and Experimental Hematology, 1st Medicine Faculty, Charles University, Prague, Czech Republic. CELL, the Czech Leukemia Study Group for Life, Brno, Czech Republic.
700    1_
$a Pecherkova, Pavla $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic.
700    1_
$a Belohlavkova, Petra $u CELL, the Czech Leukemia Study Group for Life, Brno, Czech Republic. 4th Department of Internal Medicine Hematology, Charles University Faculty Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic.
700    1_
$a Vrbacky, Filip $u 4th Department of Internal Medicine Hematology, Charles University Faculty Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic.
700    1_
$a Machova Polakova, Katerina $u Institute of Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic. katerina.machova@uhkt.cz. Institute of Clinical and Experimental Hematology, 1st Medicine Faculty, Charles University, Prague, Czech Republic. katerina.machova@uhkt.cz. CELL, the Czech Leukemia Study Group for Life, Brno, Czech Republic. katerina.machova@uhkt.cz.
773    0_
$w MED00002664 $t Journal of experimental & clinical cancer research CR $x 1756-9966 $g Roč. 36, č. 1 (2017), s. 55
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28420426 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180521101312 $b ABA008
999    __
$a ok $b bmc $g 1300280 $s 1013496
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 36 $c 1 $d 55 $e 20170418 $i 1756-9966 $m Journal of experimental and clinical cancer research $n J Exp Clin Cancer Res $x MED00002664
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace